iBio, Inc. (NYSE:IBIO – Get Free Report) shares were down 7.1% on Tuesday . The stock traded as low as $2.55 and last traded at $2.60. Approximately 94,416 shares were traded during trading, a decline of 92% from the average daily volume of 1,128,257 shares. The stock had previously closed at $2.80.
iBio Price Performance
The company has a current ratio of 3.37, a quick ratio of 3.37 and a debt-to-equity ratio of 0.04. The firm’s fifty day moving average price is $2.56 and its two-hundred day moving average price is $2.25.
iBio (NYSE:IBIO – Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.46) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.46). As a group, research analysts predict that iBio, Inc. will post -1.74 EPS for the current fiscal year.
About iBio
iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.
See Also
- Five stocks we like better than iBio
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Beyond NVIDIA: Top 5 Semiconductor Stocks to Watch for 2025
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Netflix Is On Track To Hit $1,000 By Christmas
- Dividend Capture Strategy: What You Need to Know
- UMAC Stock Climbs Amid Trump Jr. Appointment and Meme Stock Hype
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.
